New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
12:27 EDTABAXAbaxis upgraded to Hold from Sell at Feltl
Feltl upgraded Abaxis to Hold following the company's Q4 report, noting that the company believes it has worked through its channel issues. The firm raised its price target on the shares to $38.50 from $33.75.
News For ABAX From The Last 14 Days
Check below for free stories on ABAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
07:08 EDTABAXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use